Position in PTGX
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$650,654
+$82,970 QoQ
Shares Held
5,308
-1.4% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#194
of 341 holders
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HighTower Advisors, LLC holds $312,855,129 across 115 Biotechnology names. PTGX ranks #38 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INBX |
Inhibrx Biosciences, Inc.
|
870,551 | $82,484,707 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
64,650 | $40,311,861 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
105,045 | $31,621,696 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
49,020 | $24,349,704 | |
| 5 | RPRX |
Royalty Pharma plc
|
285,630 | $16,015,274 | |
| 6 | EXEL |
Exelixis, Inc.
|
291,162 | $15,842,124 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
56,313 | $13,783,733 | |
| 8 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
140,394 | $11,443,514 |
All Filings in PTGX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $650,654 | 5,308 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $567,684 | 5,386 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $622,472 | 7,127 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $572,161 | 8,613 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $551,594 | 9,980 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $315,210 | 6,518 | Shares | Sole | 2025-05-13 | |
| 2024-09-30 | $489,915 | 10,887 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $824,115 | 23,784 | Shares | Sole | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||